Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Allergy and Clinical Immunology|October 22, 2023
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Ana Giménez-Arnau, Koremasa Hayama, et al.
Dermatology and Therapy|May 24, 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck RegionKilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2025
Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION studyJulie McLaren, Yun Chon, Kevin S Gorski, et al.
Therapeutic Advances in Rare Disease|February 3, 2026
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trialsHenning Andersen, Jordi Díaz-Manera, Ozlem Goker-Alpan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
Journal of Forensic and Legal Medicine|July 24, 2010
Postmortem diagnosis of acute haemorrhagic pancreatitisB Suresh Kumar Shetty, Archith Boloor, Ritesh G Menezes, et al.
Angewandte Chemie (International Ed. in English)|May 18, 2012
Consequences of cooperativity in racemizing supramolecular systemsSeda Cantekin, Huub M M ten Eikelder, Albert J Markvoort, et al.
Therapeutic Advances in Rare Disease|March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe diseaseRobert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Journal of Neurology|December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
Pageof 4